These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1988574)

  • 21. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
    Kurzman ID; MacEwen EG; Rosenthal RC; Fox LE; Keller ET; Helfand SC; Vail DM; Dubielzig RR; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Dec; 1(12):1595-601. PubMed ID: 9815961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.
    Saiki I; Milas L; Hunter N; Fidler IJ
    Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
    Fogler WE; Fidler IJ
    Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.
    Asano T; Fujimaki W; McWatters A; An T; Matsushima K; Kleinerman ES
    Cancer Immunol Immunother; 1993 Nov; 37(6):408-11. PubMed ID: 8242665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
    Asano T; McIntyre BW; Bednarczyk JL; Wygant JN; Kleinerman ES
    Oncol Res; 1995; 7(5):253-7. PubMed ID: 8534931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
    Ando K; Mori K; Corradini N; Redini F; Heymann D
    Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
    Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
    Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of experimental endotoxin shock by a monocyte activator.
    Passlick B; Labeta MO; Izbicki JR; Ostertag P; Löffler T; Siebeck M; Pichlmeier U; Schweiberer L; Ziegler-Heitbrock HW
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2535-40. PubMed ID: 8585740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
    Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
    J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
    J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
    Asano T; Matsushima K; Kleinerman ES
    Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
    Hisano G; Fidler IJ
    Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity.
    Kurzman ID; Cheng H; MacEwen EG
    Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
    Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
    Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators.
    Hudson MM; Snyder JS; Jaffe N; Kleinerman ES
    Cancer Res; 1988 Sep; 48(18):5256-63. PubMed ID: 3261632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
    Tandon P; Utsugi T; Sone S
    Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
    Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
    Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.